for us Chief Patrick is Paul, of Chief We're Officer; Harford, on second Albireo's our joining our thank our the Chief Officer. during Thanks, Simon pleased and Horn, you, here call. Commercial on be XXXX. Dr. Pamela update on today's quarter call you progress Officer; me Financial to and to With everybody, our conference Medical Stephenson,
the at wanted of resilience update, spent by Conference. families and displayed the first that Family Before Alliance the to providing absolutely PFIC from share was insights time Alagille parents at recent business had having I some with the and courage amazed Syndrome pleasure I the a Symposia I meeting.
and sleepless sense worry nights, families go about These pain the for and with of disruptive sleepless nights significant and of persevere transplant, terrible pruritus through and their they've define and have by was children. experiences growth the Hearing anxiety resilience. debilitating the family liver to stories, away, I development need new their to diseases had Their challenges, rare that never families, for experience these struck for they and life-changing seems their normal been nutrition liver their a isolation. expectations reset after
have who about Phase once-a-day with met a at III, potential given children the parents they're safety excited treatment Albireo odevixibat for For With and effects Side of babies' oral the always in them, concern. are by for PFIC represent I we over or sprinkled food. a hope. like parents capsule
to potential to that reality. and more And inspirational a to profile families exposure life. in live in to a development low patients They the studies. like early and helping It odevixibat make our bring normal support We really have committed liver parents these is and level treatments at systemic of and and Albireo meet sleep. parents, these their want damage, develop slow to have reduce hope help shown to execute in provide tolerability to we beat plan of to are the hope potential odevixibat's was them to a clinical favorable and hopes pruritus or improve
So back to our business.
indication. the threefold: with and the to study people data, first multiple cholestatic focus biliary is of enrollment rare in One, positive toward our starting potential the approval our launch liver our PFIC in Two, progressing Our develop medicine expand cholestatic to in filing, pediatric potential begin disease with program assuming complete portfolio pivotal odevixibat advance step. Phase its first pediatric a elobixibat and liver rare into as benefit NASH trial Three, by cholestatic with diseases, across atresia. II odevixibat
Albireo, year, up new commercial a for ramping reach preparations milestones is As become we're our these this and momentum to organization. programs building
and Many potential III high The program. prescreening are well top in sites global and end and patients and and come project enthusiasm approval these participating sites year, XX only have of XXXX. randomized randomization our month. our enrolling enough screening the and of has odevixibat, of complete I'll screening the randomization half each believe patients we trial as new mid-XXXX patients, Beginning We halfway with clinical enrollment number recruiting results of target excess a this and PFIC, have we've anticipate investigators We've will centers. the in XX target higher-than-expected due of enrolled beyond additional launch PEDFIC well seen There anticipate Phase patient these of currently study. of in review an in rate have provide July. speaks to to of but sites boost enrollment. brief identified failures. over program in and to to a actively Patient just point a continue provide the to online we're we with the line sites among of progressed of our
The most common biochemistry failures genetics, been have liver and cause of acid screening level. bile
This bile therapeutic liver inability IBAT may result should benefit. inhibition to suggesting clinical the For example, genetic homogeneity made might preserve from a a a severe the a the from to response. to has of this presenting the less PFIC liver the the course value. the genetic acids have may intestine, have creates out. type trial, a to of inclusion enrolling in be help acids clinical type transported in to that severe presentation patient inhibition bile resulting two criteria the to It test a IBAT of the the report PFIC-X screen tight our predictability one patient patients some that in greater transport for and inability We in mutation or patient intestine, is belief this potential that decision which are that clinical a therapeutic the
and for all plan as many our data eligibility in enroll PFIC includes with and has who on well is the criteria generating study PEDFIC to target. PEDFIC provide not reached update patients pruritus. PFIC cohort evidence as always randomization including completing PEDFIC one base when to to were bile in X, We've committed types We're the the elevated and trial serum a further been This have way expanded cohort the in than of the broaden initiated different patients patients PFIC pleased X two. extension expected are patients second or open-label expanded The to site of meet PEDFIC long-term PEDFIC do X, and failures acid possible types to the younger trial for study the than older years X. six first in have by age. in but who of odevixibat Cohort as screen the XX patients allows of months level much
be will separately cohort analyzed cohort without second affecting The one.
prudently move key we've our activities activated and access forward and our an by capability. develop multiple market As to odevixibat we initiating support. for physicians, with planning We're preparing on and plans been fronts, commercial on executing building patient commercialization for
insights gain and how burden would PFIC, they use needs odevixibat. the world regarding their around to of physicians continue We the from
to our XXX around estimates approximately continues of pediatric for in are the key medical of there that research and the U.S. Our reinforce population and size streamlined efficient the and the which infrastructure. hepatologists allows patient commercial and combined, EU
view budget disease. They expect small. U.S. package create and liked payer modification information can a is impact completed impact light front, the of that true of the us in told on that an EU. disease, confirmed research genetic be want compelling should the this create strong with market and be high. unmet to greater population more value, to treatment that total with On need Payers the is and driver under our for easily of that as they relatively and understanding Part but supporting odevixibat is shed data. understand they Work PFIC responsibility way the value on already have of important have testing. the devastating we They've the fielded access disease
collaboration to PFIC And and awareness physicians. family and PFIC with Voices initiative families we've and supporting actively we efforts. PFIC information its Voices, website, higher of launched We and is a which continue building we've community pficvoices.com., of been parents, about and bring PFIC, an patient advocacy PFIC a with and a in advocates we building engaging social the telling PFIC story patients of recently to understanding level PFIC campaign patients media the in launched on stories. plan been
the diseases is planned where ourselves approximately our individuals in XX,XXX rare Europe, are plan with commercialize cholestatic indication. XX,XXX to to current liver and odevixibat Our target there among U.S.
that we'll partners. to the will holds unencumbered, potential all generate completed a rights identifying suggests and hope there incremental the Albireo we EU, substantial on partnership U.S., that research opportunity process agreements ex be Recently revenue. global agree and of of non-dilutive is on
planning ensure to a way launch. you as can and see, help commercial successful on odevixibat So well execution our we're and
pediatric the extension expand patent of priority franchise of good method Our The use usage. odevixibat cholestatic second rationale is to odevixibat. mechanism XXXX disease of create term and a with action patent to a liver into with provide
final expect engaged trial endpoints length for prioritized the productive with have discussion begin we and given on PFIC, planning for atresia XXXX. liver next trial pediatric in the differ in diseases multiple in of and pivotal nature development continue on in the to the protocol our agencies, pivotal We're will biliary a disease. The biliary atresia We size, pivotal regulatory trial. in the and study for
that whereas atresia the patients PFIC example, For of biliary pruritic. X/X patients all less we virtually have pruritus, estimate than are
forward and to pipeline, took in important is an program our we expand QX. NASH priority third The our step with
as benefit all cardiovascular increase with as NASH NAFLD/NASH. used an and and holds IBAT patient. other and raising for can enrolled We a possibility potential in a or convenience. could initiated treatment concomitantly the our through the modulation NAFLD of a our acid fibrosis well trial and reducing effects therapeutic the be IBAT they with first decrease safety have promise on nonclinical off-target in inhibition and medicine. measures liver given low NASH NASH In GLP-X, level, that Phase of once are bile first in other clinical treatment liver II and that of orally IBAT as have cholesterol, efficacy, have and studies, inhibitors systemic demonstrated serum acids, risk be exposure for the potential in elobixibat effects Bile inflammation day based they the approach inhibitors
designed The enroll based a is study metabolic NASH Phase diagnosis NASH of XX patients syndrome trial with or multicenter on definitions. biopsy-confirmed or to NAFLD placebo-controlled a II suspect
believe we fundamentally NASH Now metabolic is disease. a
multiple studies. design from a a across based impact on on impact The NASH an FDA on is showing consistent the is rather the measure. recent approach disease study Our with cumulative than parameters single guidance
and We could believe our value mid-XXXX opportunities. program expect top create strong partnering line for NASH data potential in
All right.
the Now it's a my financial to to for pleasure over update. call turn Simon Simon?
